Bank of America Corp DE Raises Holdings in TriSalus Life Sciences, Inc. (NASDAQ:TLSI)

Bank of America Corp DE raised its position in shares of TriSalus Life Sciences, Inc. (NASDAQ:TLSI - Free Report) by 120,471.6% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 178,446 shares of the company's stock after buying an additional 178,298 shares during the quarter. Bank of America Corp DE owned about 0.59% of TriSalus Life Sciences worth $894,000 as of its most recent SEC filing.

Several other institutional investors have also added to or reduced their stakes in TLSI. Renaissance Technologies LLC purchased a new position in TriSalus Life Sciences during the 4th quarter valued at approximately $67,000. Northern Trust Corp grew its holdings in shares of TriSalus Life Sciences by 22.7% in the fourth quarter. Northern Trust Corp now owns 32,112 shares of the company's stock valued at $161,000 after purchasing an additional 5,936 shares in the last quarter. Finally, Geode Capital Management LLC grew its holdings in shares of TriSalus Life Sciences by 1.9% in the fourth quarter. Geode Capital Management LLC now owns 204,137 shares of the company's stock valued at $1,023,000 after purchasing an additional 3,710 shares in the last quarter. Hedge funds and other institutional investors own 2.58% of the company's stock.

Insider Transactions at TriSalus Life Sciences

In related news, insider Richard Marshak sold 6,597 shares of the company's stock in a transaction on Monday, May 19th. The shares were sold at an average price of $5.18, for a total value of $34,172.46. Following the completion of the sale, the insider now owns 69,101 shares in the company, valued at $357,943.18. This represents a 8.71% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Insiders sold a total of 16,125 shares of company stock worth $83,528 over the last ninety days. Company insiders own 27.50% of the company's stock.

TriSalus Life Sciences Trading Up 0.9%

TLSI opened at $5.39 on Friday. The firm has a 50 day moving average of $5.39 and a two-hundred day moving average of $5.13. The firm has a market capitalization of $203.95 million, a PE ratio of -2.16 and a beta of 0.47. TriSalus Life Sciences, Inc. has a 12-month low of $3.50 and a 12-month high of $6.62.

TriSalus Life Sciences (NASDAQ:TLSI - Get Free Report) last posted its quarterly earnings data on Thursday, May 15th. The company reported ($0.33) EPS for the quarter, missing the consensus estimate of ($0.20) by ($0.13). The business had revenue of $9.17 million during the quarter, compared to the consensus estimate of $9.04 million. During the same period in the prior year, the business posted ($0.60) EPS. As a group, analysts predict that TriSalus Life Sciences, Inc. will post -1.55 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

TLSI has been the subject of several recent research reports. Lake Street Capital initiated coverage on TriSalus Life Sciences in a research report on Thursday, February 13th. They issued a "buy" rating and a $10.00 price target for the company. Canaccord Genuity Group reaffirmed a "buy" rating and set a $11.00 price objective on shares of TriSalus Life Sciences in a research note on Friday, March 28th. Six analysts have rated the stock with a buy rating and two have given a strong buy rating to the company's stock. According to MarketBeat.com, the company currently has an average rating of "Buy" and an average price target of $10.75.

About TriSalus Life Sciences

TriSalus Life Sciences, Inc, a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.